Experimental Animals

TK-NOG Mouse

Notice of commencement of distribution of TK-NOG mice and human liver chimeric mice

Trial distribution of TK-NOG mice, which have been favored for a long time, is to be terminated.

Regarding the distribution of TK-NOG mice and human liver chimeric mice engrafted with human hepatocytes hereafter, please contact our business partner, In-Vivo Science Inc.

Distribution to academic organizations will be continued by CIEA.

TK-NOG mouse
Formal name NOD.Cg-PrkdcscidIl2rgtm1SugTg(Alb-UL23)7-2/ShiJic
Abbreviated name NOG-Tg(Alb-UL23)7-2/ShiJic
Age at distribution (weeks) 6-week old male♂(genes for transfection already selected)
Distribution conditions

Upon use of TK-NOG mice, please agree with the following terms on the Type 2 Use of genetically modified organisms related to research and development, etc.

  1. Submit a separate research protocol if you would like to use them.
  2. Use only for the purpose described in the research protocol.
  3. Do not distribute or sell to any third party.
  4. Do not perform in-house breeding, mating with other strains, genetic modification, etc.
  5. Submit the use results report at the end of the business year.
  6. With regard to rearing this mouse, comply with related laws and regulations, perform appropriate rearing management in the rearing facility at P1A level, and strive to prevent runaway, loss, theft, etc.
Microbial monitoring We will provide you with the most recent monitoring results of the "immunodeficient animal core set" as per the ICLAS Monitoring Center (within 1 month).
We will perform testing of other parameters separately.
Human liver chimeric mice
Distribution conditions The Type 2 Use of genetically modified organisms related to research and development, etc., is applicable. Please agree with the same terms as those for TK-NOG mice.
Microbial monitoring Mice with chimeric rates of 1) ≧70% and 2) ≧40% are available.
Please contact In-Vivo Science Inc. for details.
  1. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing.
    Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, Masek M, Michie SA, Glenn J, Peltz G.
    PLoS Med. 2014 Apr 15;11(4):e1001628.
  2. Can 'humanized' mice improve drug development in the 21st century?
    Peltz G.
    Trends Pharmacol Sci. 2013 May;34(5):255-60.
  3. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativeity of human cytochrome P450 in humanized TK-NOG mice.
    Yamazaki H, Suemizu H, Murayama N, Utoh M, Shibata N, Nakamura M, Guengerich FP.
    Chem Res Toxicol. 2013 Mar 18;26(3):486-9.
  4. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.
    Yamazaki H, Suemizu H, Shimizu M, Igaya S, Shibata N, Nakamura M, Chowdhury G, Guengerich FP.
    Chem Res Toxicol. 2012 Feb 20;25(2):274-6.
  5. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.
    Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, Suemizu H.
    Biochem Biophys Res Commun. 2011 Feb 18;405(3):405-10.
Experimental Animals


Copyright © Central Institute for Experimental Animals